Cytek Biosciences reaffirms its 2024 revenue guidance, expecting full year 2024 revenue in the range of $203 million to $213 million, representing growth of 5% to 10% over full year 2023, assuming no change in currency exchange rates. For the year ending December 31, 2024, Cytek Biosciences expects to report positive net income.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.92 USD | -0.84% | -4.21% | -35.09% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.09% | 784M | |
+10.22% | 226B | |
+12.99% | 198B | |
+18.09% | 142B | |
+28.66% | 111B | |
+2.09% | 65.26B | |
+14.70% | 54.36B | |
+6.68% | 50.94B | |
+8.29% | 44.8B | |
+2.60% | 36.8B |
- Stock Market
- Equities
- CTKB Stock
- News Cytek Biosciences, Inc.
- Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024